ClinicalTrials.gg
RecruitingNCT05437562Updated Nov 18, 2026

Randomized Clinical Trial for Ewing Amputation in the VA

An interventional study of Ewing Below Knee Amputation and Standard Below Knee Amputation in Peripheral Arterial Disease, sponsored by VA Office of Research and Development. Recruiting at 3 sites in United States. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Peripheral Arterial Disease by VA Office of Research and Development — 5 open to participants now, 6 under way, 1 of them phase 3. Peripheral Arterial Disease · VA Office of Research and Development.

Planned enrollment
5th of 15
120 · median 56
Started
2026
the only one that year
No phase
12 of 16
3 open now
Registered
12th of 16
by date

Among the 16 studies in Peripheral Arterial Disease by VA Office of Research and Development, this one is the 5th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 12 with no phase, and was the 12th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

5 of the 16 studies in Peripheral Arterial Disease by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Peripheral Arterial Disease by VA Office of Research and Development, or all of them as a file.
02

Study summary

This study follows the Pilot Investigation of Ewing Amputation for Veterans with PAD Undergoing a Below Knee Amputation. The 2 year pilot feasibility phase has concluded recruitment and enrollment.

The current phase is a 5 year randomized study of Ewing Below Knee Amputation vs. Standard Below Knee Amputation. If Veterans participate, they will be randomized to either Ewing Amputation or Standard Below Knee Amputation.

The scientific premise motivating this proposal is that Ewing Amputation is a promising surgical technique that may improve walking metrics in dysvascular Veterans by providing a better residual limb and improving pain and balance.

In preparation of this proposal, we have formed multi-disciplinary surgical teams at each site, and we have been supported by a clinical trial planning meeting to garner the considerable expertise in rehabilitation and amputee assessment from VA and DOD experts to assist in the design of this proposal, testing the overall hypothesis that: Ewing Amputation can help Veterans walk.

Read the detailed description

Major amputations lead to significant challenges for Veterans and their loved ones. Thus, amputations and the care of amputees are a major focus of the VHA. Hence, the tripartite goals of the VHA Amputation System of Care (ASoC) are to: provide state of the art care, maximize health and independence, and to be the provider of choice for amputated Veterans. Veterans undergo \~1000 transtibial amputations (TTA) annually, making TTA a commonly performed operation in the VA. Almost all Veterans requiring TTA are dysvascular with peripheral artery disease (PAD) and/or diabetes. TTA is a safe operation with a low 30-day mortality rate, and ambulation with prosthesis rates are much better for TTA versus transfemoral amputations (TFA). Since \~50% of Veterans are satisfied with their ambulation after major amputation, improving ambulation is an important benchmark forward in the care of Veterans. Importantly, the lower ambulation rates in Veterans are attributed to modifiable sequelae of major amputation, including: slower wound healing9,10; chronic pain, imbalance, and falls. Excitingly, new techniques can improve pain and balance and may improve wound healing/prevent falls. Ewing amputation (EA) recreates the agonist-antagonist myoneural interface (AMI) maintaining muscle tension, proprioception and limiting fibrofatty muscle degeneration of muscle flaps. EA also creates regenerative peripheral neural interfaces (RPNI) to improve pain control. Thus, EA may have a significant benefit to Veterans undergoing TTA.

03

Conditions studied

  • Peripheral Arterial Disease

Keywords

  • amputation
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Veterans who have reasonable blood flow to heal a TTA (defined as palpable popliteal pulse or palpable femoral pulse with popliteal artery signal)
  • Veterans with an expectation of participating in rehabilitation and resuming ambulation after amputation (defined by the Veteran interest, recent ambulation by the Veteran, ability to participate in physical therapy as deemed by the investigators' physical therapy team)
  • Veterans who will be undergoing below knee amputation for reasons other than infection (uninfected patients) or Veterans who have had foot infection localized below the ankle (retinaculum uninfected) that has been adequately debrided and treated with appropriate antibiotic course.

Exclusion criteria

Exclusion Criteria:

  • Veterans with end-stage renal disease (ESRD)
  • Veterans requiring major amputation due to infection that includes the ankle retinaculum
  • Veterans deemed to have inadequate blood flow to heal a TTA
  • Veterans who cannot participate in rehabilitation or are not expected to be able to ambulate with a prosthesis for any reason
  • Veterans who were randomized for their other limb (to prevent Veteran from the possibility of having 2 different amputations)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Ewing Amputation

    Ewing Below Knee Amputation - incorporates RPNI and AMI

    Procedure: Ewing Below Knee Amputation

  • Experimental
    Standard Below Knee Amputation

    Standard Below Knee Amputation

    Procedure: Standard Below Knee Amputation

Interventions

  • ProcedureEwing Below Knee Amputation

    Ewing Below Knee Amputation - incorporates RPNI and AMI

  • ProcedureStandard Below Knee Amputation

    Standard Below Knee Amputation

06

What researchers measure

Primary outcomes

  1. PROMIS Numeric Rating Scale

    Patient reported rating scale to assess pain intensity and pain interference.

    Time frame: 12 months

  2. Socket Comfort Score

    Patient reported rating scale to assess socket fit of prosthesis.

    Time frame: 12 months

  3. Phantom and Residual Limb Questionnaire

    Patient reported questionnaire to assess sensation in phantom limb.

    Time frame: 12 months

  4. Lower Extremity Amputee Data Collection Form

    Patient reported questionnaire to assess amputation system of care.

    Time frame: 12 months

  5. Lower Limb Mobility Rating Scale

    Patient reported scale to assess movement with prosthetic leg.

    Time frame: 12 months

  6. Amputee Single Item Mobility Measure

    Patient reported measure to assess current level of mobility.

    Time frame: 12 months

  7. Activities-specific Balance Scale

    Patient reported scale to assess balance while performing every day activities.

    Time frame: 12 months

  8. Self-Reported Falls Measure

    Patient reported one question survey to calculate falls in the previous month.

    Time frame: 12 months

  9. RAND Health Survey

    Patient reported survey to assess general health while performing usual activities.

    Time frame: 12 months

  10. CRIS Fixed Form Instrument

    Patient reported rating scale to assess usual activities in previous two weeks.

    Time frame: 12 months

  11. Patient Two Minute Walk Test

    To measure distance patient can walk without assistance in 2 minutes.

    Time frame: 12 months

  12. Patient Timed Up and Go Test

    To measure amount of time patient walks 3 meters.

    Time frame: 12 months

  13. Berg Balance Scale

    To assess the patient's sitting and standing balance levels.

    Time frame: 12 months

  14. Amputee Mobility Predictor Questionnaire

    To measure the patient's sitting, standing, turning and walking/stepping with and without prosthesis.

    Time frame: 12 months

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2030, 48 months after the start.

Of 261 non-industry interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's planned 48 months is above that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2022
First posted
Jun 29, 2022
StartActual
Feb 2, 2026
Primary completionEst.
Feb 2, 2030
CompletionEst.
Feb 2, 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers
1 update, last Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Minor edits only
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05437562
Responsible party
Sponsor
First posted
Jun 29, 2022
Start date
Feb 2, 2026
Primary completion
Feb 2, 2030 (estimated)
Completion
Feb 2, 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

Luke P Brewster, MD
Contact
Luke.Brewster@va.gov
(404) 321-6111 ext. 7084
Madhur Sancheti, MS
Contact
madhur.sancheti@va.gov
(404) 321-6111 ext. 206478
Luke P Brewster, MD
principal investigator · Atlanta VA Medical and Rehab Center, Decatur, GA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion